Gilead Sciences has signed an agreement to acquire Repare Therapeutics’ polymerase theta (Polθ) ATPase inhibitor, RP-3467.

Zydus Lifesciences Global FZE, a subsidiary of Zydus, has entered into an agreement with Bioeq for the US commercialisation ...

With the latest batch’s agreements, only three out of the 17 drugmakers initially targeted by Trump have not signed pricing ...

The Amicus acquisition will bolster BioMarin’s rare disease portfolio, while potentially growing the company’s future revenue ...

Genentech, a subsidiary of the Roche Group, has received the US FDA accelerated approval for Lunsumio VELO SC formulation to ...

Shares rose 5% for Novo Nordisk on the approval of oral Wegovy as it looks to ease market pressures with a significant ...

MEDIPOST has announced a multi-year exclusive partnership with Teikoku Seiyaku to commercialise CARTISTEM, an allogeneic stem ...

Eli Lilly has now submitted a new drug application (NDA) for GLP-1RA orforglipron to the FDA for use in adults with obesity.

As we head into the new year, now is the time to look back on the activity seen in the pharma space in 2025 and consider what ...

China’s focus on first or best-in-class oncology drugs and innovative R&D will help it to secure further licensing deals in ...

Ipsen first looked to add an ADC to its portfolio via a deal that would have been worth up to $900m with Sutro Biopharma in ...

Poised to become law, the BIOSECURE Act will have ramifications for certain US-China pharmaceutical relationships.